AbbVie’s Maviret (glecaprevir/pibrentasvir) Receives EC’s Marketing Authorization as Eight-Week Regimen for Treatment-Naïve Chronic HCV Patients with Genotype 3 and Compensated Cirrhosis

Shots:

• The approval is based on P-IIIb EXPEDITION-8 study assessing Maviret in 343 treatment naïve chronic HCV patients with compensated cirrhosis across all major genotypes (GT1-6) for 8wks.
• The P-IIIb EXPEDITION-8 study results: GT1- 6 patients achieving SVR₁₂ (97.7%); GT3 patients achieving SVR₁₂ (95.2%); one case of virologic failure and no case of discontinuation was reported
• Maviret is a combination of NS3/4A protease & NS5A inhibitor and is now available as an 8-week regimen for treatment-naïve, HCV patients without cirrhosis & with compensated cirrhosis, regardless of genotype in the EU

Click here ­to­ read full press release/ article | Ref: AbbVie | Image: AbbVie